S. Chawla, S. Grunberg, R. Gralla
May 1, 2003
Citations
4
Influential Citations
222
Citations
Quality indicators
Journal
Cancer
Abstract
The neurokinin‐1 antagonist aprepitant (EMEND™; Merck Research Laboratories, West Point, PA) has been shown to reduce chemotherapy‐induced nausea and vomiting when it is given with a 5‐hydroxytryptamine‐3 receptor antagonist and dexamethasone. The current study sought to define the most appropriate dose regimen of oral aprepitant.